An elevated tumor sialylation profile also has strong implications for therapy, and research over the past few years has highlighted that sialylation and especially ST6GAL1 convey resistance to several types of cancer therapy, including immunotherapy, small-molecule inhibitors, radiotherapy, and chemotherapy. The gene discussed is ST6GAL1; the disease is neoplasm.